Immune-related cardiotoxicities predict immune checkpoint inhibitors treatment for advanced non-small cell lung cancer: a retrospective multi-center study.

ABSTRACT:

Background

Immune checkpoint inhibitor (ICI) therapy is a cornerstone in the treatment of advanced non-small cell lung cancer (NSCLC), but immune-related cardiotoxicities remain a concern. Whether immune-related cardiotoxicities serve as independent prognostic predictors for NSCLC remains debated. This study aimed to investigate the prognostic value of immune-related cardiotoxicities and develop a predictive model for survival outcomes in NSCLC patients receiving ICI therapy.

Methods

This retrospective multi-center study included NSCLC patients from nine centers who received at least one ICI cycle from 2019 to 2024. Demographic and clinical indicators were analyzed for associations with overall survival (OS). A prognostic model based on Cox regression and a nomogram was deve

SUBMITTER: Sun H 

PROVIDER: S-EPMC12557700 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature